keyword
MENU ▼
Read by QxMD icon Read
search

Pediatric allogenic stem cell transplant

keyword
https://www.readbyqxmd.com/read/29778713/concluding-commentary-on-current-trends-to-enhance-the-clinical-safety-of-pediatric-transfusion-focusing-on-prevention-of-untoward-complications-of-hsc-transplantation-newer-strategies-for-improving-the-standards-of-safety-quality-of-stem-cells-expansion-for
#1
REVIEW
Irena Sniecinski, Jerard Seghatchian
Clinical practice and related diagnostic, development and research [DDR] strategies in pediatric transfusion and transplantation cover a broad range of multidisciplinary studies, performed by many professionals involved in this most challenging clinical field [1]. This commentary on the current position and future perspectives in pediatric transfusion field is aimed to highlight major unresolved transfusion complications in pediatric patients, namely red blood cell and platelet alloimmunisation, and new ones such as nosocomial infection, thrombosis and multi-organ failure...
May 16, 2018: Transfusion and Apheresis Science
https://www.readbyqxmd.com/read/29777573/quantiferon-cytomegalovirus-assay-a-potentially-useful-tool-in-the-evaluation-of-cmv-specific-cd8-t-cell-reconstitution-in-pediatric-hematopoietic-stem-cell-transplant-patients
#2
Bilio Paouri, Alexandra Soldatou, Eftihia Petrakou, Maria Theodosaki, Charalampos Tsentidis, Katerina Kaisari, Christina Oikonomopoulou, Minos Matsas, Eugenios Goussetis
Pediatric HSCT recipients are at high risk for CMV reactivation due to their immature immune system and therapy following transplantation. Reconstitution of CMV-specific T-cell immunity is associated with control and protection against CMV. The clinical utility of monitoring CMV-specific CMI to predict CMV viremia in pediatric HSCT patients using the Quantiferon-CMV (QIAGEN® ) test was investigated prospectively. Thirty-seven pediatric allogeneic HSCT recipients were enrolled from 3/2010-6/2012. CMV viremia was detected via weekly real-time PCR...
May 18, 2018: Pediatric Transplantation
https://www.readbyqxmd.com/read/29772352/allogeneic-stem-cell-transplantation-from-hla-mismatched-donors-for-pediatric-patients-with-acute-lymphoblastic-leukemia-treated-according-to-the-2003-bfm-and-2007-international-bfm-studies-impact-of-disease-risk-on-outcomes
#3
Jean-Hugues Dalle, Adriana Balduzzi, Peter Bader, Arjan Lankester, Isaac Yaniv, Jacek Wachowiak, Anna Pieczonka, Marc Bierings, Akif Yesilipek, Petr Sedlacek, Marianne Ifversen, Sabina Sufliarska, Jacek Toporski, Evgenia Glogova, Ulrike Poetschger, Christina Peters
RATIONAL: Allogeneic HSCT is beneficial for pediatric patients with relapsed or (very) high-risk ALL in remission. A total of 1115 consecutive patients were included in the ALL SCT 2003 BFM study and the ALL SCT 2007-International study and were stratified according to relapse risk (Standard vs. High vs. Very High Risk of Relapse) and donor type (Matched Sibling vs. Matched Donor vs. Mismatched Donor). PATIENTS AND METHODS: A total of 148 patients (60% male, median age 8...
May 14, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29753677/multicenter-phase-1-2-application-of-adenovirus-specific-t-cells-in-high-risk-pediatric-patients-after-allogeneic-stem-cell-transplantation
#4
Winnie Ip, Juliana M F Silva, Hubert Gaspar, Arindam Mitra, Shreenal Patel, Kanchan Rao, Robert Chiesa, Persis Amrolia, Kimberly Gilmour, Gul Ahsan, Mary Slatter, Andrew R Gennery, Robert F Wynn, Paul Veys, Waseem Qasim
BACKGROUND: Adenovirus (ADV) reactivation can cause significant morbidity and mortality in children after allogeneic stem cell transplantation. Antiviral drugs can control viremia, but viral clearance requires recovery of cell-mediated immunity. METHOD: This study was an open-label phase 1/2 study to investigate the feasibility of generating donor-derived ADV-specific T cells (Cytovir ADV, Cell Medica) and to assess the safety of pre-emptive administration of ADV-specific T cells in high-risk pediatric patients after allogeneic hematopoietic stem cell transplantation (HSCT) to treat adenoviremia...
May 9, 2018: Cytotherapy
https://www.readbyqxmd.com/read/29753157/treosulfan-fludarabine-and-low-dose-total-body-irradiation-for-children-and-young-adults-with-acute-myeloid-leukemia-or-myelodysplastic-syndrome-undergoing-allogeneic-hematopoietic-cell-transplantation-a-prospective-phase-ii-trial-of-the-pediatric-blood-and
#5
Eneida R Nemecek, Ralf A Hilger, Alexia Adams, Bronwen E Shaw, Deidre Kiefer, Jennifer Le-Rademacher, John E Levine, Gregory Yanik, Wing Leung, Julie-An Talano, Paul Haut, David Delgado, Neena Kapoor, Aleksandra Petrovic, Roberta Adams, Rabi Hanna, Hemalatha Rangarajan, Jignesh Dalal, Joseph Chewning, Michael R Verneris, Stacy Epstein, Lauri Burroughs, Evelio D Perez-Albuerne, Michael A Pulsipher, Colleen Delaney
This multicenter study evaluated a treosulfan-based regimen in children and young adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplant (HCT). Forty patients with median age 11 years (1-19) underwent allogeneic HCT for AML in first (n=18), second (n=11), third or greater remission (n=3); or MDS (n=8) using bone marrow (n=25), peripheral blood stem cells (n=5) or cord blood (n=9). The regimen consisted of body surface area (BSA)-based treosulfan 10 g/m2 /day (BSA ≤ 0...
May 9, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29744996/hematopoietic-stem-cell-transplantation-without-in-vivo-t-cell-depletion-for-pediatric-aplastic-anemia-a-single-center-experience
#6
Sidan Li, Bin Wang, Lingling Fu, Yilin Pang, Guanghua Zhu, Xuan Zhou, Jie Ma, Yan Su, Maoquan Qin, Runhui Wu
For young patients, HLA-MRD HSCT is the first-line treatment of SAA. However, due to China's birth control policy, few patients could find suitable sibling donors and HLA-MUD. More and more transplantation centers have used Haplo-D as the donor source for young adult and pediatric patients. However, studies with larger amount of pediatric patients are rare. We retrospectively analyzed the data of children with AA who were treated with allogeneic HSCT and compared the therapeutic efficacy of Haplo-HSCT and MRD/MUD group...
May 10, 2018: Pediatric Transplantation
https://www.readbyqxmd.com/read/29743395/-allogeneic-hematopoietic-stem-cell-transplantation-using-myeloablative-conditioning-including-total-body-irradiation-for-pediatric-acute-lymphoblastic-leukemia-a-single-center-retrospective-analysis
#7
Mamoru Honda, Yuki Arakawa, Ryota Kawakami, Toshikazu Itabashi, Masato Yanagi, Koji Sasaki, Kentaro Watanabe, Kiyotaka Isobe, Makiko Mori, Ryoji Hanada, Katsuyoshi Koh
This study aimed to investigate the clinical outcomes of hematopoietic stem cell transplantation (HSCT) with total body irradiation-based myeloablative conditioning (TBI-MAC) in pediatric patients with acute lymphoblastic leukemia (ALL). We retrospectively examined patients with ALL who underwent HSCT with TBI-MAC from January 2000 to August 2016 at our institute. We enrolled 67 patients with a median follow-up period of 8 years. The 5-year event-free survival (EFS) and overall survival (OS) were 51.2% and 59...
2018: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/29721197/backtracked-analysis-of-preleukemic-fusion-genes-and-dna-repair-foci-in-umbilical-cord-blood-of-children-with-acute-leukemia
#8
Milan Škorvaga, Matúš Durdík, Pavol Košík, Eva Marková, Marek Holop, Miroslav Kubeš, Judita Puškáčová, Alexandra Kolenová, Igor Belyaev
The first event in origination of many childhood leukemias is a specific preleukemic fusion gene (PFG) that arises, often in utero, in hematopoietic stem/progenitor cells (HSPC) from misrepaired DNA double strand break (DSB). An immanently elevated level of DSB and impaired apoptosis may contribute to origination and persistence of PFG and donor cell-derived leukemia in recipients of allogeneic transplantation of umbilical cord blood (UCB). We investigated DSB, apoptosis and PFG in the backtracked UCB cells of leukemic patients...
April 10, 2018: Oncotarget
https://www.readbyqxmd.com/read/29708883/graves-disease-following-allogenic-hematopoietic-stem-cell-transplantation-for-severe-aplastic-anemia-case-report-and-literature-review
#9
Ahu Paketçi, Korcan Demir, Özlem Tüfekçi, Sezer Acar, Ayhan Abacı, Şebnem Yılmaz, Ece Böber
BACKGROUND: Similar autoimmune processes (defective T-cell function) take place during the pathogenesis of aplastic anemia (AA) and Graves' disease (GD). Antithyroid drugs used for the management of GD may induce AA and GD may occur following treatment of severe aplastic anemia (SAA). CASE PRESENTATION: Clinical and laboratory investigations were performed for an 11-year-and-2-month-old girl who was referred for bilateral exophthalmus and abnormal thyroid function tests...
April 25, 2018: Journal of Pediatric Endocrinology & Metabolism: JPEM
https://www.readbyqxmd.com/read/29702996/phase-i-study-of-cord-blood-transplantation-with-intrabone-marrow-injection-of-mesenchymal-stem-cells-a-clinical-study-protocol
#10
Tatsunori Goto, Makoto Murata, Seitaro Terakura, Tetsuya Nishida, Yoshiya Adachi, Yoko Ushijima, Kazuyuki Shimada, Yuichi Ishikawa, Fumihiko Hayakawa, Nobuhiro Nishio, Satoshi Nishiwaki, Akihiro Hirakawa, Katsuyoshi Kato, Yoshiyuki Takahashi, Hitoshi Kiyoi
INTRODUCTION: Delayed hematological recovery, graft failure, and acute graft-versus-host disease (GVHD) still remain major problems in cord blood transplantation (CBT). Mesenchymal stem cells (MSCs) are known to support bone marrow stroma and promote hematopoiesis. Additionally, MSCs possess immunomodulatory properties and are used clinically for the treatment of acute GVHD. Therefore, the use of MSCs to enhance engraftment and prevent GVHD after allogeneic hematopoietic cell transplantation has been explored...
April 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29679436/fungal-infections-in-hematopoietic-stem-cell-transplantation-in-children-at-a-pediatric-children-s-hospital-in-argentina
#11
Sergio Miguel Gomez, Miguela Caniza, Alicira Fynn, Cecilia Vescina, Claudia Ruiz, Daniela Iglesias, Fernanda Sosa, Lillian Sung
Our primary objective was to describe the incidence of proven or probable invasive fungal infections (IFIs), a devastating complication of hematopoietic stem cell transplant (HSCT), in HCST in a middle-income country. Secondary objectives were to describe factors associated with IFIs and outcomes. In this single center retrospective study, pediatric patients who underwent a first allogeneic or autologous HSCT from 1998 to 2016 were included. Of the 251 HSCT recipients: 143 transplants were allogeneic and 108 were autologous...
April 20, 2018: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/29668078/adherence-and-immune-response-to-revaccination-following-hematopoietic-stem-cell-transplantation-at-a-pediatric-onco-hematology-reference-center
#12
Fernanda Gouveia-Alves, Roseane Gouveia, Valéria C Ginani, Adriana Seber, Danielle A Kuramoto, Gabriel F A Murad, Fernanda G Spina, Antonio S Petrilli, Victor G Zecchin, Celso Granato, Fabianne Carlesse, M Isabel de Moraes-Pinto
BACKGROUND: Revaccination after hematopoietic stem cell transplantation (HSCT) is necessary to compensate for the loss of immunological memory. The aims of this study were to evaluate the adherence to revaccination schedule and the humoral immune response to different vaccine antigens in HSCT pediatric and young adult patients. METHODS: Patients submitted to HSCT for over 3 years were recruited. After written informed consent, a questionnaire was filled in, the vaccination card was analyzed, a blood sample was collected and tested by ELISA for diphtheria, Haemophilus influenzae type b (Hib), hepatitis A, hepatitis B, tetanus, measles, rubella and varicella antibodies...
April 18, 2018: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/29667720/mycophenolate-mofetil-administered-every-8-hours-in-combination-with-tacrolimus-is-efficacious-in-the-prophylaxis-of-acute-graft-versus-host-disease-in-childhood-adolescent-and-young-adult-allogeneic-stem-cell-transplantation-recipients
#13
Olga Militano, Mehmet F Ozkaynak, Brinda Mehta, Carmella van deVen, Carl Hamby, Mitchell S Cairo
BACKGROUND: The optimal dose and schedule of mycophenolate mofetil (MMF) in pediatric allogeneic stem cell transplant recipients remains to be determined. We previously reported safety and pharmacokinetics of MMF at 900 mg/m2 q6h dosing. This study was conducted to investigate the efficacy of tacrolimus plus q8h MMF dosing for acute graft versus host disease (GVHD) prophylaxis in a heterogeneous population of children, adolescent, young adult allogeneic stem cell transplant recipients, utilizing multiple allogeneic donor sources...
April 18, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29653206/late-effects-screening-guidelines-after-hematopoietic-cell-transplantation-hct-for-hemoglobinopathy-consensus-statement-from-the-second-pediatric-blood-and-marrow-transplant-consortium-international-conference-on-late-effects-after-pediatric-hct
#14
Shalini Shenoy, Javid Gaziev, Emanuele Angelucci, Allison King, Monica Bhatia, Angela Smith, Dorine Bresters, Anne E Haight, Christine N Duncan, Josu de la Fuente, Andrew C Dietz, K Scott Baker, Michael A Pulsipher, Mark C Walters
Allogeneic hematopoietic cell transplantation (HCT) can halt organ damage and eliminate symptoms in hemoglobin disorders, including sickle cell disease (SCD) and thalassemia major (TM). Managing the residual manifestations of pre-HCT disease complications and the long-term effects of HCT requires systematic monitoring, follow-up, and intervention when indicated. Late complications vary with age and disease status at HCT, and with transplant variables such as preparative regimen, donor source and compatibility, and immune reconstitution...
April 10, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29620685/ebv-ptld-adenovirus-and-cmv-in-pediatric-allogeneic-transplants-with-alemtuzumab-as-part-of-pretransplant-conditioning-a-retrospective-single-center-study
#15
Margaret C Cupit-Link, Amulya Nageswara Rao, Deepti M Warad, Vilmarie Rodriguez, Shakila Khan
The risk of viral infections and reactivation occurring in the setting of pediatric allogeneic hematopoietic stem cell transplantation is a concern in the pediatric patient, especially with the use of Alemtuzumab (Campath) as a conditioning agent. The purpose of this study was to determine the incidence of Epstein-Barr virus posttransplant lymphoproliferative disorder (EBV-PTLD), cytomegalovirus (CMV), and adenovirus among pediatric recipients of alemtuzumab at our institution. We found that EBV-PTLD occurred in 2...
April 3, 2018: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/29608706/risks-and-outcomes-of-invasive-fungal-infections-in-pediatric-allogeneic-hematopoietic-stem-cell-transplant-recipients-receiving-fluconazole-prophylaxis-a-multicenter-cohort-study-by-the-turkish-pediatric-bone-marrow-transplantation-study-group
#16
Volkan Hazar, Gülsün Tezcan Karasu, Vedat Uygun, Gülyüz Öztürk, Suar Çaki Kiliç, Alphan Küpesiz, Hayriye Daloglu, Serap Aksoylar, Didem Atay, Elif Ünal Ince, Musa Karakükçü, Namik Özbek, Funda Tayfun, Savas Kansoy, Emel Özyürek, Arzu Akçay, Orhan Gürsel, Sule Haskologlu, Zühre Kaya, Sebnem Yilmaz, Atila Tanyeli, Akif Yesilipek
Invasive fungal infections (IFIs) are a major cause of infection-related morbidity and mortality in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Data from pediatric settings are scarce. To determine the incidence, risk factors and outcomes of IFIs in a 180-day period post-transplantation, 408 pediatric patients who underwent allogeneic HSCT were retrospectively analyzed. The study included only proven and probable IFIs. The cumulative incidences of IFI were 2.7%, 5.0%, and 6...
March 27, 2018: Medical Mycology: Official Publication of the International Society for Human and Animal Mycology
https://www.readbyqxmd.com/read/29588248/non-malignant-late-cutaneous-changes-after-allogeneic-hematopoietic-stem-cell-transplant-in-children
#17
Jennifer T Huang, Johanna S Song, Elena B Hawryluk, Wendy B London, Dongjing Guo, Madhumitha Sridharan, David E Fisher, Leslie E Lehmann, Christine N Duncan
BACKGROUND: There are limited pediatric data on non-malignant cutaneous changes, including autoimmune conditions and permanent alopecia, after hematopoietic stem cell transplantation (HSCT). OBJECTIVE: We sought to characterize late cutaneous changes and associated risk factors after allogeneic HSCT in children. METHODS: A cross-sectional cohort study of pediatric HSCT recipients was performed at a single institution. All participants underwent a full skin examination...
March 24, 2018: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29577525/post-hematopoietic-stem-cell-transplant-hemophagocytic-lymphohistiocytosis-or-an-impostor-case-report-and-review-of-literature
#18
Anant Vatsayan, Irina Pateva, Linda Cabral, Jignesh Dalal, Rolla Abu-Arja
HLH occurring after HSCT is a relatively rare disease. Many conditions may mimic or trigger HLH in post-HSCT period (eg, cytokine release syndrome, engraftment syndrome, graft rejection/failure, acute graft-vs-host disease, infections systemic inflammatory response syndrome/sepsis, and thrombotic microangiopathy). Moreover, this period is usually marked by febrile illness, cytopenia, and a "cytokine storm" leading to elevation of inflammatory biomarkers like ferritin and sCD25. These parameters overlap with the diagnostic criteria for HLH...
March 25, 2018: Pediatric Transplantation
https://www.readbyqxmd.com/read/29573905/autoimmune-hemolytic-anemia-aiha-following-allogeneic-hematopoietic-stem-cell-transplantation-hsct-a-retrospective-analysis-and-a-proposal-of-treatment-on-behalf-of-the-grupo-espa%C3%A3-ol-de-trasplante-de-medula-osea-en-ni%C3%A3-os-getmon-and-the-grupo-espa%C3%A3-ol-de-trasplante
#19
REVIEW
Marta González-Vicent, Jaime Sanz, José Luis Fuster, Joan Cid, Cristina Díaz de Heredia, Daniel Morillo, José María Fernández, Antonia Pascual, Isabel Badell, David Serrano, Laura Fox, Javier de la Serna, Ana Benito, José Miguel Couselo, Blanca Molina, Miguel Ángel Díaz, Miguel Ángel Sanz
Autoimmune hemolytic anemia (AIHA) is a complication of allogeneic hematopoietic stem cell transplantation (HSCT) associated with poor outcome. However, an optimal therapeutic approach is lacking. Between 2000 and 2015, 4099 allogeneic HSCT were performed in eight pediatric centers of the Grupo Español De Trasplante de Medula Osea en Niños (GETMON) and six adult centers of the Grupo Español de Trasplante Hematopoyetico (GETH). Sixty cases of AIHA were registered with a cumulative incidence of 1.5% occurring at a median of 6 months after HSCT...
March 3, 2018: Transfusion Medicine Reviews
https://www.readbyqxmd.com/read/29560765/a-retrospective-analysis-of-bloodstream-infections-in-pediatric-allogeneic-stem-cell-transplant-recipients-the-role-of-central-venous-catheters-and-mucosal-barrier-injury
#20
Chelsea Balian, Michelle Garcia, Jessica Ward
BACKGROUND: Bloodstream infections (BSIs) are a leading cause of morbidity and mortality in children undergoing hematopoietic stem cell transplant (HSCT). Indwelling central venous catheters (CVCs) increase risk for BSIs, yet mucosal barrier injury-associated laboratory-confirmed bloodstream infection (MBI-LCBI) may also occur due to translocation of pathogenic organisms from the gastrointestinal tract into the bloodstream. The purpose of this study was to determine the association between stool organisms and BSIs in children with CVCs who underwent HSCT...
March 1, 2018: Journal of Pediatric Oncology Nursing: Official Journal of the Association of Pediatric Oncology Nurses
keyword
keyword
76293
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"